Integra LifeSciences stock (US4579851036): Citi upgrade and 52-week high put valuation back in focus

Integra LifeSciences shares have drawn renewed interest on the Nasdaq in the United States this week after a combination of a broker upgrade and fresh 52-week highs pushed the U.S. medtech stock further into the spotlight. Citi analyst Joanne Wuensch raised her recommendation on the stock to Neutral from Sell and lifted the price target to USD 16 from USD 11 in a note dated late May 2026, citing easing headwinds and improved execution, according to TipRanks/The Fly as of 05/28/2026.

The upgrade comes as Integra LifeSciences has been trading near new 52-week highs, with reports from Investing.com indicating the shares recently touched around USD 16.49, up roughly 85% from the 52-week low, underscoring how the market has re-rated the company in 2026. On 05/28/2026, the stock closed at USD 16.46, marking an 8.4% gain for the day and extending an 84% advance from the prior low, according to a performance review by GuruFocus. The stock trades on Nasdaq under the ticker IART, which is the primary listing venue for the United States.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Integra LifeSciences: core business model

Integra LifeSciences focuses on specialized surgical implants and regenerative tissue products for neurosurgery, extremity reconstruction and wound care, with revenue largely driven by demand from hospitals and clinics for higher-margin, procedure-based solutions in the United States and other developed health-care systems.

Valuation metrics and multiples for Integra LifeSciences

The strong move in the share price this month has pushed Integra LifeSciences back into the valuation debate as investors weigh the rebound against underlying fundamentals and longer-term growth prospects. GuruFocus data as of 05/28/2026 show the stock changing hands at USD 16.46 with an assessed intrinsic "GF Value" of USD 23.74, implying that, on this framework, the shares trade at a discount of about 30.7 percent and are still considered undervalued despite the recent run-up. The same analysis notes that the stock's 8.4 percent jump on that day extended a robust recovery in 2026, even after the company had previously suffered a sharp market-cap contraction in 2024 and 2025.

Historical market-capitalization figures compiled by StockAnalysis illustrate the swing in sentiment: Integra LifeSciences ended 2024 with a market cap of roughly USD 1.75 billion, down 48.6 percent from a year earlier, and stood around USD 967.4 million at year-end 2025 before rebounding to about USD 1.18 billion by 05/27/2026. While detailed current P/E or EV/EBITDA multiples are not provided in those datasets, the combination of a higher share price and a still-recovering earnings base suggests that valuation is in a transition phase, with the Citi target at USD 16 broadly in line with where the Nasdaq quote has been trading in the last sessions.

Conclusion

The latest trading action in Integra LifeSciences on Nasdaq, including an 8.4 percent gain on 05/28/2026 and a move to fresh 52-week highs near USD 16.50, reflects how quickly sentiment around the U.S. medical-technology group has improved in 2026. Citi's decision to lift its rating to Neutral and raise its target to USD 16 has reinforced that shift, aligning broker expectations more closely with the current share price while still leaving room for investors to monitor how execution, earnings trends and sector dynamics will shape the next phase of the valuation story.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.